Wells Fargo & Company Concert Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$4.34 - $5.84 $34 - $46	8 Added 2.8%	294 $1,000
Q3 2022 Nov 14, 2022	BUY	$4.27 - $7.2 $465 - $784	109 Added 61.58%	286 $2,000
Q2 2022 Aug 12, 2022	BUY	$2.8 - $6.36 $58 - $133	21 Added 13.46%	177 $1,000
Q1 2022 May 16, 2022	BUY	$2.73 - $3.94 $2 - $3	1 Added 0.65%	156 $1,000
Q4 2021 Feb 14, 2022	SELL	$2.69 - $4.22 $81,103 - $127,232	-30,150 Reduced 99.49%	155 $0

Q3 2021 Nov 15, 2021	SELL	$3.17 - $4.15 $453 - $593	-143 Reduced 0.47%	30,305 $99,000
Q2 2021 Aug 16, 2021	SELL	$3.77 - $5.24 $109,820 - $152,641	-29,130 Reduced 48.89%	30,448 $128,000
Q1 2021 May 13, 2021	SELL	$4.86 - $13.07 $62,314 - $167,583	-12,822 Reduced 17.71%	59,578 $298,000
Q4 2020 Feb 09, 2021	BUY	$9.48 - $12.84 $294,306 - $398,617	31,045 Added 75.07%	72,400 $915,000
Q3 2020 Nov 05, 2020	SELL	$8.67 - $10.82 $250,693 - $312,860	-28,915 Reduced 41.15%	41,355 $406,000
Q2 2020 Aug 13, 2020	BUY	$7.8 - $11.52 $182,091 - $268,934	23,345 Added 49.75%	70,270 $700,000
Q1 2020 May 14, 2020	BUY	$5.98 - $13.09 $280,611 - $614,248	46,925 New	46,925 $415,000

Ticker CNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,934,600
Description
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has s...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.